Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...7891011121314151617...123124»
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Real-world evidence, Real-world:  A real-world drug safety surveillance study of lenvatinib from the FAERS database. (Pubmed Central) -  Aug 15, 2024   
    FGFR4, PDGFRA, and KIT (Lenvatinib targets) are potentially linked to cholecystitis, cholangitis, and hepatic encephalopathy. We identified Lenvatinib-associated AEs and discovered new AEs that will be useful for clinical monitoring and risk assessment.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  PLANE-PC: Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (clinicaltrials.gov) -  Aug 14, 2024   
    P2,  N=50, Recruiting, 
    Prospective controlled studies are needed to determine the efficacy of this approach. Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Biomarker, Enrollment closed, Monotherapy:  Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients (clinicaltrials.gov) -  Aug 7, 2024   
    P2,  N=30, Active, not recruiting, 
    Thus, LEN-New FP can serve as a breakthrough therapy for advanced HCC based on appropriate case selection. Recruiting --> Active, not recruiting
  • ||||||||||  Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
    Treatment with tildrakizumab of hidradenitis and Fournier (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_2739;    
    This poster highlights the importance of being aware of the side effects of new oncological therapies. The sequential appearance of the 3 side effects and the fact that they disappeared after the discontinuation of the therapy with pd1-p21 and multikinase inhibitors seem to indicate a causal relationship.
  • ||||||||||  Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Biomarker, Journal, Machine learning:  Integrating bioinformatics and machine learning methods to analyze diagnostic biomarkers for HBV-induced hepatocellular carcinoma. (Pubmed Central) -  Aug 3, 2024   
    Molecular docking results showed that the key genes could spontaneously bind to the anti-hepatocellular carcinoma drugs Lenvatinib, Regorafenib, and Sorafenib with strong binding activity. Therefore, ECT2, NDC80, and RACGAP1 may serve as potential biomarkers for the diagnosis of HBV-HCC and as targets for the development of targeted therapeutic drugs.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    A CASE OF PEMBROLIZUMAB-INDUCED PULMONARY HYPERTENSION AND PLEURAL EFFUSION (Convention Center Exhibit Hall: Rapid Fire Area 4C) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_4521;    
    More than one side effect can occur simultaneously, such as in our patient. This case underlines the importance of diligent workup necessary to reach the diagnosis as it is of exclusion.
  • ||||||||||  Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Case report: Translational treatment of unresectable intrahepatic cholangiocarcinoma: Tislelizumab, Lenvatinib, and GEMOX in one case. (Pubmed Central) -  Jul 30, 2024   
    Tumor-free surgical margins (R0) resection of patients with advanced ICC after combination of immune, targeted and chemotherapy is rare, and there are almost no cases of complete postoperative remission. The GEMOX regimen in combination with Tislelizumab and Lenvatinib has a good antitumor efficacy and safety profile, and may be a feasible and safe translational treatment option for advanced ICC.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Retrospective data, Journal, Metastases:  HAND-FOOT SYNDROME IN SORAFENIB AND LENVATINIB TREATMENT FOR ADVANCED THYROID CANCER. (Pubmed Central) -  Jul 29, 2024   
    HFS was the most frequent reason for drug reduction or discontinuation in patient treated with sorafenib. Early diagnosis of HFS is important to allow early intervention, possibly in a multidisciplinary setting, and to avoid treatment discontinuation, which is highly relevant to obtain the maximum effectiveness of systemic therapy.
  • ||||||||||  Journal, Metastases:  Approaches to Treating High Risk and Advanced Renal Cell Carcinoma (RCC): Key Trial Data That Impacts Treatment Decisions in the Clinic. (Pubmed Central) -  Jul 29, 2024   
    Subsequently, adjuvant pembrolizumab has shown a benefit in overall survival, whereas trials of neoadjuvant and adjuvant nivolumab, adjuvant atezolizumab, and adjuvant ipilimumab plus nivolumab have all been negative...The CARMENA study raised important questions about the role of cytoreductive nephrectomy given the advances in VEGFR TKI therapy but was characterized by accrual difficulties and a significant number of patients not receiving treatment according to the study protocol. Two ongoing studies (NORDIC-SUN and PROBE) seek to further address the role of cytoreductive nephrectomy in the doublet therapy era.
  • ||||||||||  Review, Journal, Checkpoint inhibition:  The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer. (Pubmed Central) -  Jul 26, 2024   
    In the first-line treatment setting, options include pembrolizumab alone or in combination with bevacizumab, as well as atezolizumab combined with a backbone platinum-based chemotherapy plus bevacizumab...For endometrial cancer, pembrolizumab monotherapy, pembrolizumab in combination with lenvatinib, and dostarlimab are currently approved as second-line treatment options...Although the inclusion of these agents in clinical practice has led to improved overall response rates and survival outcomes, many patients still lack benefits, possibly due to multiple intrinsic and adaptive resistance mechanisms to immunotherapy. This review aims to highlight the rationale for utilizing ICIs and their current role, while also delineating the proposed mechanisms of resistance to ICIs in cervical and endometrial cancer.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Metastases:  Hyperthyroidism Due to Functioning Metastatic Bone Lesions of Follicular Thyroid Carcinoma Treated With Lenvatinib. (Pubmed Central) -  Jul 26, 2024   
    The patient developed hypothyroidism, which continued after the methimazole was stopped, suggesting that lenvatinib suppressed the hyperthyroidism. To our best knowledge, this is the first report of a patient with functioning bone lesions of metastatic FTC in whom hyperthyroidism was controlled by lenvatinib without radioactive iodine therapy.
  • ||||||||||  DGFIT nachgefragt (Hall A / Level 0) -  Jul 26, 2024 - Abstract #DGU2024DGU_355;    
    AT and ZC are of great importance in daily practice. In the first line, TKI/IO therapy is predominantly used, with differences in the combination (IO/TKI, IO/IO, TKI mono) and substance combination TKI/IO (L/P, A/P, C/N) between universities, hospitals and practices.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date, Checkpoint inhibition, Metastases:  Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Na (clinicaltrials.gov) -  Jul 25, 2024   
    P2,  N=30, Recruiting, 
    In the first line, TKI/IO therapy is predominantly used, with differences in the combination (IO/TKI, IO/IO, TKI mono) and substance combination TKI/IO (L/P, A/P, C/N) between universities, hospitals and practices. Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2024 --> Jun 2025
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Combination therapy:  Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies (clinicaltrials.gov) -  Jul 24, 2024   
    P1,  N=70, Recruiting, 
    Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2024 --> Jun 2025 Withdrawn --> Recruiting